Investing Profile

Jasper Bos

InvestorVC
General Partner at Forbion
forbion.comAmsterdam, Netherlands
Photo of Jasper Bos, General Partner at Forbion

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Hotmail Network
4895 CONNECTIONS
Hotmail Network
4895 CONNECTIONS
Hotmail Network
4895 CONNECTIONS
Hotmail Network
4895 CONNECTIONS
Hotmail Network
4895 CONNECTIONS
cb
Forbion General Partner
$100K - $5.0M
$1.5M
12
CompanyStageDateRound SizeTotal Raised
Braveheart Bio
Series ANov 2025$190M
$190M
CellCentric
Series CMay 2025$120M
$380M
Co-investors: Laura Stoppel (RA Capital Management)
Engrail Therapeutics
Series BMar 2024$160M
$220M
Co-investors: Stacie Weninger (F-Prime Capital Partners), Peter Bisgaard (Pivotal bioVenture Partners), Heath Lukatch (Novo Holdings), Niall O’Donnell (RiverVest)
Precirix
Series BMar 2022$88M
$130M
Co-investors: Ohad Hammer (Xtripe Angels), Simone Botti (INKEF Capital), Marten Steen (HealthCap)
Anaveon
Series BDec 2021$120M
$160M
Co-investors: Florian Müllershausen (Novartis Venture Fund), Ohad Hammer (Xtripe Angels), Denis Patrick (Pfizer Venture Investments)
Inthera Bioscience
Series AJun 2018$5M
Series AMay 2017$11M
SeedDec 2015$4M
$20M
Co-investors: Mark Krul (Aglaia Oncology Funds), Nanna Luneborg (Forbion), Keno Gutierrez (BGV (BioGeneration Ventures))
Prexton Therapeutics
Series BFeb 2017$31M
Series AFeb 2015$10M
$41M
Co-investors: Alan O'Connell (Seroba Life Sciences), Marco Boorsma (Forbion)
ARTSaVIT
Series AJan 2017$6M
$6M
Health Economics Researcher HotmailPresent
PhD research fellow Centraal Uitvoeringsorgaan voor de Studentenorganisaties (CUOS)Present
Health Economics and Strategy Analyst NVIPresent
Head Product Development /business development HotmailPresent
Associate HotmailPresent
Board Member EpiTherapeutics ApSPresent
Member of the Board of Directors Galecto, Inc.Present
Board Member Asceneuron SAPresent
Chairman Of The Board Of Directors HotmailPresent
Board Member HotmailPresent
Senior Director MS Ventures Healthcare Business of MerckPresent
Member of the Board of Directors Metabomed Ltd.Present
Vice President, Head of Healthcare Fund M Ventures M VenturesPresent
Senior Vice President & Managing Director M VenturesPresent
Board Member ANAVEON AGPresent
Board Member enGenePresent
Board Member Engrail TherapeuticsPresent
Board Member CatalYm GmbHPresent
Board Member CellCentricPresent
Board Member Braveheart BioPresent
General Partner ForbionPresent
Forbion European Acquisition Corporation (NASDAQ: FRBN) Chief Executive Officer ForbionPresent
University of Groningen MSc Pharmacy
University of Groningen PhD pharmacy, pharmacoeconomics